Michel Dahan Insider Trading $AKBA Akebia Therapeutics, Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Michel Dahan.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Michel Dahan. Michel Dahan is SVP, Chief Business Officer in Akebia Therapeutics, Inc. ($AKBA) and SVP, Chief Operating Officer in Akebia Therapeutics, Inc. ($AKBA).
Michel Dahan in Akebia Therapeutics, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Michel Dahan: SVP, Chief Operating Officer, SVP, Chief Business Officer
Holdings: 265,550 shares
Current Value: $2,623,634
Latest Transaction: Apr 01 2021
$AKBA Market Capitalization: $177.33M
$AKBA Previous Close: $9.88
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Michel Dahan in Akebia Therapeutics, Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 01 2021 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Operatin ... | Sell | S | 3.40 | 1,211 | 4,117 | 265,550 | 266.8 K to 265.6 K (-0.45 %) |
| Mar 18 2021 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Operatin ... | Grant | A | 0.00 | 11,648 | 0 | 266,761 | 255.1 K to 266.8 K (+4.57 %) |
| Mar 02 2021 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Operatin ... | Option Exercise | A | 3.46 | 110,000 | 380,600 | 110,000 | |
| Mar 02 2021 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Operatin ... | Sell | S | 3.40 | 7,945 | 26,982 | 255,113 | 263.1 K to 255.1 K (-3.02 %) |
| Mar 02 2021 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Operatin ... | Sell | S | 3.40 | 6,602 | 22,421 | 263,058 | 269.7 K to 263.1 K (-2.45 %) |
| Mar 02 2021 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Operatin ... | Grant | A | 0.00 | 62,000 | 0 | 269,660 | 207.7 K to 269.7 K (+29.86 %) |
| Mar 02 2020 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Operatin ... | Option Exercise | A | 8.87 | 120,000 | 1,064,400 | 120,000 | |
| Mar 02 2020 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Operatin ... | Sell | S | 8.70 | 6,972 | 60,656 | 204,960 | 211.9 K to 205 K (-3.29 %) |
| Mar 02 2020 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Operatin ... | Grant | A | 0.00 | 65,000 | 0 | 211,932 | 146.9 K to 211.9 K (+44.24 %) |
| Apr 12 2019 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Business ... | Sell | D | 7.70 | 11,909 | 91,699 | 146,932 | 158.8 K to 146.9 K (-7.50 %) |
| Dec 13 2018 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Business ... | Payment of Exercise | F | 8.94 | 23,385 | 209,062 | 93,841 | 117.2 K to 93.8 K (-19.95 %) |
| Oct 04 2017 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Business ... | Sell | S | 19.64 | 1,398 | 27,457 | 95,826 | 97.2 K to 95.8 K (-1.44 %) |
| Oct 02 2017 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Business ... | Sell | S | 19.30 | 5,000 | 96,500 | 97,224 | 102.2 K to 97.2 K (-4.89 %) |
| Aug 17 2017 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Business ... | Sell | S | 15.00 | 5,000 | 75,000 | 102,224 | 107.2 K to 102.2 K (-4.66 %) |
| Jul 06 2017 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Business ... | Sell | S | 14.26 | 1,399 | 19,947 | 107,224 | 108.6 K to 107.2 K (-1.29 %) |
| Feb 23 2017 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Business ... | Option Exercise | A | 0.00 | 62,500 | 0 | 62,500 | |
| Feb 23 2017 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Business ... | Grant | A | 0.00 | 39,500 | 0 | 110,024 | 70.5 K to 110 K (+56.01 %) |
| Jan 03 2017 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Business ... | Sell | S | 10.49 | 1,629 | 17,089 | 70,524 | 72.2 K to 70.5 K (-2.26 %) |
| Oct 04 2016 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Business ... | Sell | S | 8.95 | 1,401 | 12,546 | 72,153 | 73.6 K to 72.2 K (-1.90 %) |
| Jul 06 2016 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Business ... | Sell | S | 7.47 | 1,402 | 10,468 | 73,554 | 75 K to 73.6 K (-1.87 %) |
| Apr 05 2016 | AKBA | Akebia Therapeutic ... | Dahan Michel | SVP, Chief Business ... | Sell | S | 9.41 | 1,401 | 13,183 | 74,956 | 76.4 K to 75 K (-1.83 %) |
Page: 1